When comparing RCT to real-life data , the decrease in HbA1c from baseline with sulfonylurea treatment is smaller in real life than in RCTs , whereas the reduction with vildagliptin is essentially the same , suggesting that the full power of treatment is retained in real life for vildagliptin but not for sulfonylureas , possibly due to fear of hypoglycaemia .